Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2025Cancer

Integrating surgery and targeted therapies in the management of recurrent/metastatic gastrointestinal stromal tumors

View Full Paper
Ask AI
Bookmark
Share

Authors

MYMiao YanXZXinhua ZhangMLMingzhe Li

Discussion

Loading...

Member takes

Overview

Analysis shows improved clinical outcomes and quality of life with targeted therapies in GIST patients, suggesting enhanced treatment strategies.

Key Points

  • Surgery following targeted therapy shows improved outcomes in patients with advanced gastrointestinal stromal tumors.
  • Key factors include treatment response and timing of surgical intervention, influencing clinical decisions.
  • Recent evidence highlights the role of imatinib as a first-line treatment in conjunction with surgical approaches.
  • Multidisciplinary care may extend the effectiveness of targeted therapies, enhancing patient-centered treatment approaches.

Cite This Study

Yan et al. (2025) studied this question.

synapsesocial.com/papers/69402a7e2d562116f2902146https://doi.org/10.1002/cncr.70151
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions2026
  2. 2Treatment research after failure of fourth‐line standard therapy for advanced gastrointestinal stromal tumors: A review2025 · 1 citations
  3. 3Adjuvant therapy for resectable gastrointestinal stromal tumors: evidence, controversies, and practical guidance2026
  4. 4Prognostic factors for metastatic gastrointestinal stromal tumors treated with cytoreductive surgery: a retrospective cohort study.2025
  5. 5Adjuvant treatment of gastrointestinal stromal tumors (GIST)—state of the art, controversies, and future directions2026